Navigation Links
URMC and Temple announce drug discovery partnership
Date:8/18/2011

The University of Rochester Medical Center (URMC) and Temple University School of Pharmacy have announced a partnership that will help translate novel medical research into new drugs for treating diseases.

"This is a perfect marriage of the world class drug discovery and medicinal chemistry programs of Temple University with the strong biomedical expertise of URMC and its faculty," said Stephen Dewhurst, Ph.D., chair of the URMC Department of Microbiology and Immunology. "I am excited by the opportunities this creates to explore innovative therapeutic approaches and targets."

"We are pleased and excited to establish this relationship with the University of Rochester Medical Center and its scientists and faculty," said Magid Abou-Gharbia, Ph.D., Director of Temple University's Moulder Center for Drug Discovery Research, based at the School of Pharmacy. "The disease program areas of URMC overlap significantly with those of the Moulder Center. The two organizations bring complementary experience and skills to the table and the combination of the two will undoubtedly lead to many new drug discovery projects and increase the chances of identifying new drugs for treating unmet medical needs."

Abou-Gharbia who previously worked as senior vice president of Discovery Research at Wyeth for 26 years has led the Moulder Center for Drug Discovery Research since its creation in 2008. The Center, which is located at Temple University in Philadelphia, is home to a unique, state-of-the-art laboratory that brings together pharmaceutical talent, instrumentation, and software to create one of the nation's top centers for integrated drug research.

The partnership reflects a growing trend in medical research in which academic institutions have become more directly involved in the drug discovery process, a role that has historically been filled by the pharmaceutical and biotech industries. As drug companies cut back on in-house research and development and become more risk-averse, they are increasingly looking to universities to conduct the early stage research necessary to identify promising new discoveries. For academic institutions, this means playing a more active role in identifying and guiding new compounds from the earliest stages of research along the path to becoming a new drug.

The partnership complements URMC's strength in fundamental biomedical research; specifically, identifying molecular and genetic "targets" that trigger disease. Over the last five years, the University of Rochester has received more than $1.9 billion in external research funding much of it focused in the areas of cancer, cardiovascular disease, neuromedicine, musculoskeletal disease, and immunology and infectious disease. The more recently established Moulder Center has already received over $10 million dollars in funding from private donations, federal grants, contract research and a recent Temple University Drug Discovery Research Initiative.

The agreement enables scientists at the two institutions to collaborate and move these discoveries to the next stage of research by identifying compounds that act upon these new targets and may ultimately form the basis for new therapeutics. URMC scientists will work with Moulder Center's medicinal chemistry and other drug development capabilities to rapidly screen large numbers of compounds to identify novel drug candidates that can undergo a battery of pre-clinical tests in the lab and in animal models necessary to ensure that they are stable, not toxic, and act as intended.

Some 30 URMC research projects have already been identified as potential candidates for this collaboration. These include novel approaches that could lead to new treatments for bacterial pathogens such as Methicillin-Resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii, which are notorious for their ability to evade conventional drug treatments and are widely regarded as two of the most important bacterial threats to health. Other ongoing URMC research is aimed at developing treatments for fungal diseases caused by Candida albicans and Cryptococcus neoformans, pathogens that affect premature infants, patients receiving cancer chemotherapy and organ transplants, and those living with HIV/AIDS.


'/>"/>

Contact: Mark Michaud
mark_michaud@urmc.rochester.edu
585-273-4790
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. First Ever Virtual Autism Conference Featuring Temple Grandin and 16 speakers to discuss: “Things To Know About Autism” April 10th-11th.
2. Temple receives $3.7 million to study parenting styles effect on childhood obesity
3. Temple-led study finds widening gap between distracted driving and legislation
4. Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results
5. CustomerCentric Selling and Kadient Announce Joint Event in Boston to Launch Strategic Partnership for Sales Enablement and Improvement
6. Connecture, Inc. Announces Partnership with MedicareCRM
7. Chiquita Announces Support for School Salad Bar Campaign
8. Team Health Holdings, Inc., Announces Fourth Quarter and Fiscal 2009 Financial Results
9. MDS Announces Agreements to Divest MDS Pharma Services Early Stage Business
10. MyDietShopz.com Announces Biggest Losers Contest - Share Your Story To Inspire Others
11. Rocketboy Media Wins Award for Masonic Lodge Web Site; Announces Signing of Several New Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Our high-octane society demands higher ... sharpest brain. , Power On, a mental performance enhancer from Modus Nutrition, provides ... Each capsule contains Cognizin® Citicoline, a branded form of the brain health nutrient ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy ... The technology is so cutting edge, in fact, the U.S. Food and Drug ... procedures. However, successful patient outcomes in certain clinical stem cell procedures have shown ...
(Date:2/22/2017)... ... 2017 , ... Secure Exchange Solutions, the leading provider of ... health information exchanges, physicians and patients, announced today that SES Direct earned the ... IT Module Certification via Drummond Group LLC, an Authorized Certification Body (ACB). This ...
(Date:2/22/2017)... ... 2017 , ... South Bend’s Lunkerville, the award-winning TV series that catches real ... Water (HOW), a non-profit organization dedicated to helping military veterans relax, rehabilitate, and reintegrate ... traveling to Lake Denmark, New Jersey, to fish with war veteran Justin Vail from ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... advanced data analytics to accurately understand each Medicare Advantage member’s risk, identify ... given population. This new solution helps transform the HCC Risk Adjustment process ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017 The top ... are Olympus Corporation, Nikon Corporation, and Leica Microsystems. ... in the overall market in 2015. The oligopolistic ... through result-oriented research and development activities and mergers ... focus on expanding their business to emerging economies ...
(Date:2/22/2017)... -- Corin Group announced today the launch of the Humelock ... with both a massive rotator cuff tear and a ... cuff tear arthropathy, causes pain and reduced mobility in ... Reversed Shoulder System, which was developed by FX Solutions, ... Lyon, France , received FDA clearance for ...
(Date:2/22/2017)... India , February 22, 2017 ... Radio Synthesis Modules Market: Global Opportunity Analysis and Industry Forecast, ... worth $20 million in 2015 and projected to reach $32 ... 2016 to 2022. North America accounted ... and unit volumes, whereas Asia-Pacific region ...
Breaking Medicine Technology: